

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2710615

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BIOTICA TECHNOLOGY LIMITED (IN CREDITORS VOLUNTARY LIQUIDATION)	12/09/2013
RECEIVING PARTY DATA	
Name:	NEUROVIVE PHARMACEUTICAL AB
Street Address:	MEDICON VILLAGE
City:	LUND
State/Country:	SWEDEN
Postal Code:	223 81
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13575212
CORRESPONDENCE DATA	
Fax Number:	(215)563-4044
Phone:	215-563-4100
Email:	docketclerk@ddhs.com
<i>Correspondence will be sent via US Mail when the email attempt is unsuccessful.</i>	
Correspondent Name:	ROBERT C. NETTER, JR.
Address Line 1:	1601 MARKET STREET
Address Line 2:	SUITE 2400
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19103-2307
ATTORNEY DOCKET NUMBER:	5241-P05584US00
NAME OF SUBMITTER:	ROBERT C. NETTER, JR., PH.D.
Signature:	/Robert C. Netter, Jr./
Date:	02/03/2014
Total Attachments: 2 source=5584US00_Biotica_Neurovive_Assignment#page1.tif source=5584US00_Biotica_Neurovive_Assignment#page2.tif	

ASSIGNMENT

WHEREAS, **Biotica Technology Limited (in creditors voluntary liquidation)**, having Company number 03243295, hereinafter referred to as ASSIGNOR, is named owner of an invention entitled: **SANGLIFEHRIN BASED COMPOUNDS**, described and claimed in an application for Letters Patent of the United States signed by ASSIGNORS under U.S. Application No. 13/575,212.

WHEREAS, Neurovive Pharmaceutical AB, a institution organized and existing under and by virtue of the laws of Sweden, and engaged in business at Medicon Village, 223 81 Lund, Sweden, hereinafter referred to as ASSIGNEE, is desirous of acquiring the said invention and any and all applications for Letters Patent and any and all Letters Patent of the United States and foreign countries which may be issued therefor;

NOW THEREFORE THIS IS TO WITNESS that in consideration of the sum of One Dollar (\$1.00) paid to ASSIGNOR by ASSIGNEE, the receipt of which is hereby acknowledged, and for other good and valuable consideration, ASSIGNOR has sold, assigned and set over and hereby does sell, assign and set over, unto ASSIGNEE, its successors and assigns, for the territory of the United States of America and for all foreign countries, ASSIGNOR'S entire right, title and interest in and to the aforesaid inventions, as well as any improvement thereof, and any and all applications for Letters Patents which have been, or hereafter may be, filed on said invention or any said improvement, including any and all divisional, renewal, substitute, continuation and continuation-in-part application, together with the right to claim priority accruing from said applications, and all Letters Patent which may be granted on any said application(s) for said invention or any said improvement, and all extension(s) and reissue(s) thereof.

And ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue any and all Letters Patent of the United States to ASSIGNEE, its successors and assigns, as the owner of all right, title and interest therein.

This Assignment constitutes the entire understanding between the parties and neither Biotica Technology Limited (in creditors voluntary liquidation) nor its liquidators shall be obligated or held liable by any condition or representation other than those expressly stated herein.

Notwithstanding any other honorar in this Assignment, it is agreed that nothing in this Assignment imposes on Biotica Technology Limited (in creditors voluntary liquidation) any obligation or liability in addition to those in the agreement pursuant to which the assignment is entered into.

This assignment takes effect under and is governed by the laws of England.

IN WITNESS WHEREOF, this assignment has been executed on the day and month indicated below.




[Insert Name] Christopher Nigel McKay

[Insert Title/Signatory Capacity], Joint liquidator

On Behalf of Biotica Technology Limited (in creditors voluntary liquidation), as agent and without personal liability

9 Dec. 2013

Date



[Insert Name] Mikael Brönnegård

[Insert Title/Signatory Capacity] CEO

On Behalf of Neurovive Pharmaceutical AB

9 Dec. 2013

Date